Olfr371 Inhibitors

Olfr371 is a member of the olfactory receptor protein family, functioning as a G-protein-coupled receptor (GPCR) responsible for the recognition and transduction of odorant signals. With a 7-transmembrane domain structure, it plays a pivotal role in initiating neuronal responses that lead to the perception of smell. The olfactory receptor gene family, including Olfr371, is the largest in the genome, highlighting its significance in olfactory perception. The nomenclature for these genes is unique to the organism. To inhibit Olfr371, various chemicals have been identified, each with distinct mechanisms of action. Mometasone suppresses the cAMP signaling pathway, disrupting GPCR-mediated transduction. Niflumic acid interferes with the receptor's transmembrane domain, hindering odorant recognition. Pertussis toxin targets the G protein in olfactory signal transduction, reducing Olfr371 activation. Haloperidol modulates downstream effectors, impacting dopamine receptors and altering olfactory perception indirectly.

Budesonide and fluticasone both suppress cAMP signaling, impeding GPCR-mediated transduction and Olfr371 activation. Lidocaine and tetracaine alter the receptor's transmembrane domain, affecting conformation and normal function. Diphenhydramine and prochlorperazine modulate downstream effectors, influencing histamine and dopamine receptors, respectively, indirectly impacting Olfr371 function. In summary, these inhibitors act through diverse mechanisms to interfere with Olfr371, disrupting its normal function in odorant signal transduction. Understanding these chemical interactions provides valuable insights into the complex regulatory pathways involved in olfactory perception.